EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Extracellular Vesicle‐Mediated Nucleolin Transfer in Glioblastoma: A Targetable Axis Driving Blood‐Tumour Barrier Formation

Hongzhen Chen, Junyi Zhao, Fang Qiu, Zhuqian Wang, Jie Li, Lingqiang Zhang, Aiping Lu, Chao Liang iD

Journal of Extracellular Vesicles · 2026

DOI: 10.1002/jev2.70268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Hongzhen Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Glioblastoma, Phosphoproteins, Blood-Brain Barrier. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shenzhen Medical Research Fund, National Key Research and Development Program of China, National Natural Science Foundation Council of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) remains a significant therapeutic challenge. While GBM‐derived extracellular vesicles (EVs) are known to remodel the normal blood‐brain barrier (BBB) into a blood‐tumour barrier (BTB), the underlying mechanism is largely not understood. Here, we reveal that nucleolin (NCL) is transferred via GBM‐derived EVs to the surface of brain endothelial cells, where it promotes BTB formation. Furthermore, the NCL‐specific aptamer AS1411 exploits this pathway, crossing the BTB through receptor‐mediated transcytosis and selectively entering GBM cells in an NCL‐dependent manner. Proteolysis‐targeting chimeras (PROTACs), heterobifunctional molecules that recruit E3 ligases to degrade target proteins, show therapeutic potential but are hindered by inefficient brain penetration in GBM. Capitalizing on the BTB‐penetrating capability of AS1411 and our prior finding that AS1411 can intracellularly recruit the E3 ligase MDM2 via employing NCL as a molecular bridge, we engineered AS1411‐based PROTACs against VEGFR2 and EGFR. These PROTACs induced NCL‐ and MDM2‐dependent ubiquitination and degradation of VEGFR2 or EGFR in GBM cells, demonstrating potent anti‐tumour activity. Collectively, our findings identify EV‐transferred NCL as a key mediator of BTB formation and a functional transcytosis receptor for AS1411, providing a promising strategy for developing BTB‐permeable, targeted therapy for GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA-Binding ProteinsGlioblastomaPhosphoproteinsBlood-Brain BarrierExtracellular VesiclesBrain NeoplasmsNucleolinHumansProteolysis Targeting ChimeraCell Line, TumorAnimalsOligodeoxyribonucleotidesProto-Oncogene Proteins c-mdm2Endothelial CellsErbB ReceptorsMiceVascular Endothelial Growth Factor Receptor-2Aptamers, Nucleotide

Stichwörter der Autor:innen

AS1411PROTACsblood‐tumour barrierglioblastomanucleolin

Substanzen

NucleolinRNA-Binding ProteinsPhosphoproteinsProteolysis Targeting ChimeraOligodeoxyribonucleotidesAGRO 100Proto-Oncogene Proteins c-mdm2ErbB ReceptorsVascular Endothelial Growth Factor Receptor-2MDM2 protein, human

Autor:innen und Institutionen

  • Department of Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China.
  • Institute of Integrated Bioinformedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
  • Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, China.
  • State Key Laboratory of Proteomics, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.
  • Institute of Systems Medicine and Health Sciences, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
  • Shanghai University of Traditional Chinese Medicine, Shanghai, China.

ORCID-Profile: Chao Liang

Förderung

  • Shenzhen Medical Research Fund
  • National Key Research and Development Program of China
  • National Natural Science Foundation Council of China
  • Shenzhen Science and Technology Program
  • Hong Kong General Research Fund
  • Hong Kong RGC Theme-based Research Scheme
  • Shenzhen LingGene Biotech Co., Ltd
  • Shenzhen Science and Technology Innovation Program

Zitieren

APA

Chen, H., Zhao, J., Qiu, F., Wang, Z., Li, J., Zhang, L., Lu, A., & Liang, C. (2026). Extracellular Vesicle‐Mediated Nucleolin Transfer in Glioblastoma: A Targetable Axis Driving Blood‐Tumour Barrier Formation. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70268

Vancouver

Chen H, Zhao J, Qiu F, Wang Z, Li J, Zhang L, et al. Extracellular Vesicle‐Mediated Nucleolin Transfer in Glioblastoma: A Targetable Axis Driving Blood‐Tumour Barrier Formation. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70268

BibTeX
@article{Chen2026,
  author = {Chen, Hongzhen and Zhao, Junyi and Qiu, Fang and Wang, Zhuqian and Li, Jie and Zhang, Lingqiang and Lu, Aiping and Liang, Chao},
  title = {Extracellular Vesicle‐Mediated Nucleolin Transfer in Glioblastoma: A Targetable Axis Driving Blood‐Tumour Barrier Formation},
  journal = {Journal of Extracellular Vesicles},
  year = {2026},
  doi = {10.1002/jev2.70268}
}
Kostenlos starten →